Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?

The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader, followed closely by Novo Nordisk.However, other giants in the industry have been attempting to enter the field, and Pfizer (NYSE: PFE) is among them. Although the company has encountered some setbacks in this quest, it hasn't given up, as evidenced by a recent $5 billion investment that will allow it to make another run at the goal.Let's figure out what Pfizer is doing, and whether the company's shares are worth investing in.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool